ORIC Pharmaceuticals

Rank#5800

Market Cap1.33B

CountryUnited States

Summary

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

History

ORIC Pharmaceuticals was founded in 2007 and is located in San Francisco, California. The company was created to focus on improving the lives of cancer patients and their families by advancing the understanding and treatment of cancer.ORIC has conducted a number of clinical studies in both solid tumors and hematologic malignancies.

Mission

At ORIC, our mission is to discover, develop and commercialize targeted therapies that provide innovative and meaningful treatment options to patients. We strive to build an organization that values transparency, excellence, and accountability and is dedicated to collaboration and delivering on our commitments.

Vision

Our vision is to become a leader in the development of highly targeted therapies for the treatment of cancer and serious medical diseases.

References

https://in.investing.com/equities/oric-pharmaceuticals-inc

https://finance.yahoo.com/quote/ORIC/profile?p=ORIC

https://www.crunchbase.com/organization/oric-pharmaceuticals

https://companiesmarketcap.com/

https://www.oricpharma.com

Leadership team

Dr. Richard A. Heyman Ph.D. (Co-Founder, Independent Chairman & Member of Scientific Advisory Board)

Dr. Jacob M. Chacko M.B.A., M.D. (Pres, CEO & Director)

Mr. Dominic G. Piscitelli CPA, CPA, M.B.A. (Chief Financial Officer)